Safety use of hydroxychloroquine and its combination with azithromycin in the context of Sars-CoV-2 outbreak: Clinical experience in a Belgian tertiary center
(2020) Travel Medicine and Infectious Disease — Vol. 36, p. 101788 [1-2] (2020)
Files
2020_Pothen_Travel_Med_Infect_Dis.pdf
Preprint
Open Access - Adobe PDF
- 1.22 MB
Details
- Authors
- Abstract
- Dear Editor, Based on studies showing in vitro antiviral activity of chloroquine (CQ) and hydroxychloroquine (HCQ) on SARS-CoV-2 (1), Belgian COVID interim guidelines rapidly (March 13th, 2020) recommended treating hospitalized patients suffering from severe COVID-19 with HCQ, 400 mg bid the first day followed by 200 mg bid for 4 additional days (for GFR > 30 ml/min). [...]
- Affiliations
Citations
Pothen, L., Yildiz, H., De Greef, J., Penaloza-Baeza, A., Beauloye, C., Belkhir, L., & Yombi, J. C. (2020). Safety use of hydroxychloroquine and its combination with azithromycin in the context of Sars-CoV-2 outbreak: Clinical experience in a Belgian tertiary center. Travel Medicine and Infectious Disease, 36, 101788 [1-2]. https://doi.org/10.1016/j.tmaid.2020.101788 (Original work published 2020)